Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 12/20 | 0.56 |
| ▸ | AKT1 | P31749 | 8/20 | 0.55 |
| ▸ | MTOR | P42345 | 8/20 | 0.55 |
| ▸ | NTRK1 | P04629 | 5/20 | 0.52 |
| ▸ | AURKA | O14965 | 3/20 | 0.52 |
| ▸ | GSK3B | P49841 | 3/20 | 0.52 |
| ▸ | MARK1 | Q9P0L2 | 3/20 | 0.52 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.49 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | RET | P07949 | 4/20 | 0.47 |
| ▸ | LCK | P06239 | 2/20 | 0.47 |
| ▸ | SRC | P12931 | 2/20 | 0.47 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4085610 | 0.92 | PDGFRB (0.57) | PDPK1AKT1MTORNTRK1AURKA | |
| SCHEMBL4081490 | 0.87 | PDPK1 (0.55) | PDPK1AKT1MTORNTRK1AURKA | |
| SCHEMBL4076329 | 0.84 | PDGFRB (0.63) | PDPK1AKT1MTORNTRK1AURKA | |
| SCHEMBL1940398 | 0.83 | PDGFRB (0.63) | PDPK1AKT1MTORNTRK1AURKA | |
| SCHEMBL4086357 | 0.83 | NTRK1 (0.53) | PDPK1AKT1MTORNTRK1AURKA | |
| SCHEMBL1941537 | 0.83 | PDGFRB (0.50) | PDPK1AKT1MTORNTRK1AURKA | |
| SCHEMBL4251376 | 0.83 | NTRK1 (0.68) | PDPK1AKT1MTORNTRK1AURKA | |
| SCHEMBL4088005 | 0.80 | NTRK1 (0.73) | PDPK1AKT1MTORNTRK1AURKA | |
| SCHEMBL4089428 | 0.80 | PDGFRB (0.63) | PDPK1AKT1MTORNTRK1AURKA | |
| SCHEMBL4076616 | 0.79 | NTRK1 (0.61) | PDPK1AKT1MTORNTRK1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595325-B2 | Substituted pyrrolo[2,3-d]pyrimidine derivatives useful in cancer treatment | PFIZER INC. (US) | 2009-09-29 | — | — | US | disclosed |
| EP-1773836-A1 | PYRROLOPYRIMIDINE DERIVATIVES USEFUL IN CANCER TREATMENT | Pfizer Products Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20060035912-A1 | Pyrrolopyrimidine derivatives useful in cancer treatment | PFIZER INC | 2006-02-16 | — | — | US | disclosed |
| WO-2005116035-A1 | PYRROLOPYRIMIDINE DERIVATIVES USEFUL IN CANCER TREATMENT | PFIZER PRODUCTS INC. (US) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035912-A1 | Pyrrolopyrimidine derivatives useful in cancer treatment | TP53, DPYD, CCNT1 | PDPK1 947/4885AKT1 1601/4885MTOR 2126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.